Investigational Site Number : 7920001

Adana 01330

1 studies enrolling now · 2 studies all time

What they study most

Hemophilia, Sickle Cell Disease

Studies at this site

• The Efficacy and Safety of Rilzabrutinib in Participants Aged 10 to 65 Years With Sickle-cell Disease — Recruiting now
• Fitusiran Prophylaxis in Male Pediatric Subjects Aged 1 to Less Than 12 Years With Hemophilia A or B — Running, not enrolling